TrialArthritis care & research2022

Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial.

Jessica A Walsh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.